Biomedical Engineering Reference
In-Depth Information
21. Katritzky AR, Lobnov V, Karelson M (1994) CODESSA (Comprehensive Descriptors for
Structural and Statistical Analysis) University of Florida,Gainesville, FL.
http://www.
codessa-pro.com
22. Katritzky AR, Perumal S, Petrukhin R et al (2001) Codessa-based theoretical QSPR model for
hydantoin HPLC-RT lipophilicities. J Chem Inf Comput Sci 41:569-574
23. DRAGON software version 3.0 (2003) Todeschini R, Consonni V, Mauri A, Pavan M,
Milano, Italy.
http://disat.unimib.it/chm/Dragon.htm
24. Wold S, Ruhe A, Wold H et al (1984) The collinearity problem in linear regression. The
partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comp
5:735-743
25. Rogers D, Hopfinger AJ (1994) Application of genetic function approximation to quantitative
structure-activity relationships and quantitative structure-property relationships. J Chem Inf
Comput Sci 34:854-866
26. Cerius
2
Version 4.10 (2005) Accelrys Inc, San Diego, USA.
http://www.accelrys.com/cerius2
27. Prabhakar YS (2003) A combinatorial approach to the variable selection in multiple
linear regression: analysis of Selwood et al. data set - a case study. QSAR Comb Sci
22:583-595
28. Vaughan Williams EM (1984) A classification of antiarrhythmic actions reassessed after a
decade of new drugs. J Clin Pharmacol 24:129-147
29. Echt DS, Liebson MD, Mitchell LB et al (1991) Mortality and morbidity in patients receiving
encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med
324:781-788
30. Jurkiewicz NK, Sanguinetti MC (1993) Rate-dependent prolongation of cardiac action
potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly
activating delayed rectifier K
+
current by dofetilide. Circ Res 72:75-83
31. Hondeghem LM (1992) Development of class III antiarrhythmic agents. J Cardivasc
Pharmacol 20:S17-S22
32. Selnick HG, Liverton NJ, Baldwin JJ et al (1997) Class III antiarrhythmic activity in vivo
by selective blockade of the slowly activating cardiac delayed rectifier potassium current
IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2- trifluoroethyl)-2,3-dihydro-
1H-benzo[e][1,4]diazepin-3-yl]acetamide. J Med Chem 40:3865-3868
33. Gupta SP, Paleti A, Mekapati SB et al (2005) A quantitative structure-activity relationship
study on some Na
+
and K
+
channel blockers: role of molecular connectivity index. Lett Drug
Des Discov 2:287-290
34. Edwards G, Weston A-H (1993) The pharmacology of ATP-sensitive channels. Annu Rev
Pharmacol Toxicol 33:597-637
35. Wickenden AD (2002) K
+
Channels as therapeutic drug targets. Pharmacol Ther 94:157-182
36. Mannhold R (2004) K
ATP
channel openers: structure-activity relationships and therapeutic
potential. Med Res Rev 24:213-266
37. Mannhold R, Cruciani G, Weber H et al (1999) 6-Substituted benzopyrans as potassium
channel activators: synthesis, vasodilator properties, and multivariate analysis. J Med Chem
42:981-991
38. Agrawal VK, Singh J, Gupta M et al (2006) QSAR studies on benzopyran potassium channel
activators. Eur J Med Chem 41:360-366
39. Lebrun P, Devreux V, Hermann M et al (1989) Similarities between the effects of pinacidil
and diazoxide on ionic and secretory events in rat pancreatic islets. J Pharmacol Exp Ther
250:1011-1018
40. Quast U (1993) Do the K
+
channel openers relax smooth muscle by opening K
+
channels?
Trends Pharmacol Sci 14:332-337
41. Petit P, Hillaire-Buys D, Mir A-K et al (1992) Differential effects of cromakalim on pancreatic
vascular resistance and insulin secretion in vitro. Fundam Clin Pharmacol 6:185-190
42. Lebrun P, Antoine M-H, Devreux V et al (1990) Paradoxical inhibitory effect of cromakalim
on 86Rb outflow from pancreatic islet cells. J Pharmacol Exp Ther 255:948-954
